Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Phase 2 Terminated 6 enrolled Masonic Cancer Center, University of Minnesota Pfizer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.

Timeline

Start: 2006-01
Primary completion: 2008-11
Completion: 2008-11

Outcome

Outcome not reported

Stopped: “Drug was not available.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPG-52852	Small molecule	0.6 mg/m2	Subcutaneous
Subject	CPG-52852	Small molecule	0.8 mg/m2	Subcutaneous
Subject	CPG-52852	Small molecule	1 mg/m2	Subcutaneous
Subject	CPG-52852	Small molecule	1.2 mg/m2	Subcutaneous

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Summary

Timeline

Outcome

Drugs

Indications